Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02932943 · ClinicalTrials.gov registry record · Phase 3

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)

A Phase 3 study of Depressive Disorder, Major, sponsored by Naurex, Inc, an affiliate of Allergan.

Completed
Registry status
Phase 3
Development phase
465
Enrollment target
20
Study locations

NCT02932943 is a Phase 3 study of Depressive Disorder, Major that has completed, run by Naurex, Inc, an affiliate of Allergan. The registered enrollment target is 465 participants, above the 233-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (100% higher). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02932943, a Phase 3 study of Depressive Disorder, Major, has completed, sponsored by Naurex, Inc, an affiliate of Allergan.

COMPLETED
Registry status
Phase 3
Development phase
465 participants
Enrollment target
20
Study locations

Study Summary

This study will evaluate the efficacy, safety, and tolerability of rapastinel 450 mg compared to placebo adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD) who have a partial response to ADT.

Conditions Studied

Depressive Disorder, Major

Interventions

  • DRUG Placebo
  • DRUG Rapastinel

Study Locations (20)

California

  • Southern California Research LLC. - Beverly Hills
  • ATP Clinical Research Inc. - Costa Mesa
  • Pharmacology Research Institute - Encino
  • Collaborative Neuroscience Network, LLC - Garden Grove
  • Synergy San Diego - Lemon Grove
  • Pharmacology Research Institute - Los Alamitos
  • Excell Research - Oceanside
  • Anderson Clinical Research - Redlands
  • Thomas M. Shiovitz, M.D., Inc., DBA California Neuroscience Research Medical Group, Inc., - Sherman Oaks
  • Viking Clinical Research - Temecula
  • Pacific Clinical Research Medical - Upland

Florida

  • Meridien Research - Bradenton
  • MD Clinical - Hallandale
  • Clinical Neuroscience Solutions, Inc - Jacksonville
  • Meridien Research - Lakeland

Georgia

  • Institute for Advanced Medical Research - Alpharetta
  • Atlanta Center for Medical Research - Atlanta

Connecticut

  • Comprehensive Psychiatric Care - Norwich

Massachusetts

  • Adams Clinical Trials - Watertown

Nevada

  • Altea Research - Las Vegas

Trial Details

FieldValue
Enrollment Target 465 participants
Start Date 2016-10-15
Est. Completion 2018-11-08
Phase Phase 3

Sponsor

Naurex, Inc, an affiliate of Allergan

18 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02932943

The ClinicalTrials.gov registry entry for NCT02932943 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 465 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 233-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (100% higher). The listed sponsor is Naurex, Inc, an affiliate of Allergan, which has 18 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Depressive Disorder, Major appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02932943 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT02932943 about?

NCT02932943 is a clinical study titled "A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)". This study will evaluate the efficacy, safety, and tolerability of rapastinel 450 mg compared to placebo adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD) who have a partial response to ADT.

What is the current status of trial NCT02932943?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 465 participants. The study started on 2016-10-15. Estimated completion is 2018-11-08.

What conditions does trial NCT02932943 study?

This clinical trial studies the following conditions: Depressive Disorder, Major.

What interventions are being tested in trial NCT02932943?

The interventions under investigation include: Placebo (DRUG), Rapastinel (DRUG).

Who is sponsoring clinical trial NCT02932943?

This trial is sponsored by Naurex, Inc, an affiliate of Allergan, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02932943 being conducted?

This trial has 20 study locations across California, Connecticut, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Depressive Disorder, Major

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Depressive Disorder, Major

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.